ATE138071T1 - Lipidhilfstoffe für verabreichung durch die nase und örtliche anwendung - Google Patents

Lipidhilfstoffe für verabreichung durch die nase und örtliche anwendung

Info

Publication number: ATE138071T1
Authority: AT; Austria
Prior art keywords: lipid; excipient; nose; administration; relatively low
Prior art date: 1989-02-17

Application number

AT90904004T

Other languages

English (en)

Inventor

Alan L Weiner

Original Assignee

Liposome Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-02-17

Filing date

1990-02-14

Publication date

1996-06-15

1990-02-14 Application filed by Liposome Co Inc filed Critical Liposome Co Inc

1996-06-15 Application granted granted Critical

1996-06-15 Publication of ATE138071T1 publication Critical patent/ATE138071T1/de

Links

150000002632 lipids Chemical class 0.000 title abstract 7
208000030507 AIDS Diseases 0.000 title 1
230000000699 topical effect Effects 0.000 title 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 5
239000002537 cosmetic Substances 0.000 abstract 3
PYVRVRFVLRNJLY-KTKRTIGZSA-N 1-oleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)COP(O)(=O)OCCN PYVRVRFVLRNJLY-KTKRTIGZSA-N 0.000 abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
231100000344 non-irritating Toxicity 0.000 abstract 2
102000055006 Calcitonin Human genes 0.000 abstract 1
108060001064 Calcitonin Proteins 0.000 abstract 1
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
235000018087 Spondias lutea Nutrition 0.000 abstract 1
238000010521 absorption reaction Methods 0.000 abstract 1
239000013543 active substance Substances 0.000 abstract 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract 1
229960004015 calcitonin Drugs 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
239000007788 liquid Substances 0.000 abstract 1
210000004379 membrane Anatomy 0.000 abstract 1
239000012528 membrane Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
210000002850 nasal mucosa Anatomy 0.000 abstract 1
231100000252 nontoxic Toxicity 0.000 abstract 1
230000003000 nontoxic effect Effects 0.000 abstract 1
150000003904 phospholipids Chemical class 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Biophysics (AREA)
Dispersion Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Otolaryngology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Manufacturing Of Micro-Capsules (AREA)
Peptides Or Proteins (AREA)

AT90904004T 1989-02-17 1990-02-14 Lipidhilfstoffe für verabreichung durch die nase und örtliche anwendung ATE138071T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US31251289A	1989-02-17	1989-02-17

Publications (1)

Publication Number	Publication Date
ATE138071T1 true ATE138071T1 (de)	1996-06-15

Family

ID=23211791

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT90904004T ATE138071T1 (de)	1989-02-17	1990-02-14	Lipidhilfstoffe für verabreichung durch die nase und örtliche anwendung

Country Status (11)

Country	Link
US (1)	US5200393A (de)
EP (1)	EP0458894B1 (de)
JP (1)	JPH05500203A (de)
KR (1)	KR0157428B1 (de)
AT (1)	ATE138071T1 (de)
AU (1)	AU639228B2 (de)
CA (1)	CA2045469A1 (de)
DE (1)	DE69027022T2 (de)
DK (1)	DK0458894T3 (de)
ES (1)	ES2089011T3 (de)
WO (1)	WO1990009385A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5891466A (en) *	1990-08-13	1999-04-06	Yesair; David W.	Mixed Liped-Bicarbonate colloidal particles for delivering drugs or calories
US6419850B1 (en) *	1991-06-03	2002-07-16	Airel-West	System and composition for decontaminating fluids
DK36492D0 (da) *	1992-03-19	1992-03-19	Novo Nordisk As	Praeparat
AU6833994A (en) *	1993-05-17	1994-12-12	Liposome Company, Inc., The	Incorporation of taxol into liposomes and gels
US6794357B1 (en) *	1993-06-24	2004-09-21	Astrazeneca Ab	Compositions for inhalation
US5747445A (en) *	1993-06-24	1998-05-05	Astra Aktiebolag	Therapeutic preparation for inhalation
IS1796B (is) *	1993-06-24	2001-12-31	Ab Astra	Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
TW402506B (en)	1993-06-24	2000-08-21	Astra Ab	Therapeutic preparation for inhalation
US6632456B1 (en)	1993-06-24	2003-10-14	Astrazeneca Ab	Compositions for inhalation
US5830853A (en) *	1994-06-23	1998-11-03	Astra Aktiebolag	Systemic administration of a therapeutic preparation
US20010003739A1 (en) *	1993-06-24	2001-06-14	Astrazeneca Ab	Systemic administration of a therapeutic preparation
SE9402455L (sv) *	1994-07-12	1996-01-13	Karlshamns Lipidteknik Ab	Biskiktspreparat
US6165976A (en)	1994-06-23	2000-12-26	Astra Aktiebolag	Therapeutic preparation for inhalation
JP4155594B2 (ja)	1994-12-22	2008-09-24	アストラゼネカ・アクチエボラーグ	エアゾール製剤
EP1283035A3 (de) *	1994-12-22	2003-03-19	AstraZeneca AB	Parathyroidhormon enthaltende therapeutische Zubereitung zur Inhalation
US6524557B1 (en)	1994-12-22	2003-02-25	Astrazeneca Ab	Aerosol formulations of peptides and proteins
US5980898A (en) *	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
US5910306A (en) *	1996-11-14	1999-06-08	The United States Of America As Represented By The Secretary Of The Army	Transdermal delivery system for antigen
US6797276B1 (en)	1996-11-14	2004-09-28	The United States Of America As Represented By The Secretary Of The Army	Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002959A1 (en) *	1996-11-14	2006-01-05	Government Of The United States	Skin-sctive adjuvants for transcutaneous immuization
US20060002949A1 (en) *	1996-11-14	2006-01-05	Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc.	Transcutaneous immunization without heterologous adjuvant
US20040258703A1 (en) *	1997-11-14	2004-12-23	The Government Of The Us, As Represented By The Secretary Of The Army	Skin-active adjuvants for transcutaneous immunization
US6221378B1 (en)	1998-02-10	2001-04-24	Generex Pharmaceuticals Incorporated	Mixed micellar delivery system and method of preparation
US7070799B1 (en) *	1998-02-10	2006-07-04	Generex Pharmaceuticals, Inc.	Method for administering insulin to the buccal region
US6017545A (en) *	1998-02-10	2000-01-25	Modi; Pankaj	Mixed micellar delivery system and method of preparation
US20030059440A1 (en) *	1998-09-01	2003-03-27	Tim Clarot	Composition and method for moisturizing nasal tissue
EP1031347B1 (de) *	1999-01-27	2002-04-17	Idea Ag	Transnasaler Transport bzw. Impfung mit hochadaptierbaren Trägern
WO2000061184A2 (en) *	1999-04-08	2000-10-19	Glenn Gregory M	Dry formulation for transcutaneous immunization
AU5936400A (en)	1999-06-04	2000-12-28	Delrx Pharmaceutical Corporation	Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US6489312B1 (en) *	1999-06-15	2002-12-03	Medimmune Oncology, Inc.	Pharmaceutical formulations comprising aminoalkyl phosphorothioates
WO2001001962A1 (en)	1999-07-05	2001-01-11	Idea Ag.	A method for the improvement of transport across adaptable semi-permeable barriers
GB9924351D0 (en) *	1999-10-14	1999-12-15	Brennan Frank	Immunomodulation methods and compositions
US6432383B1 (en)	2000-03-30	2002-08-13	Generex Pharmaceuticals Incorporated	Method for administering insulin
US20020198215A1 (en) *	2000-10-23	2002-12-26	Lino Tavares	Terazosin transdermal device and methods
EP1372708B1 (de) *	2001-02-13	2008-06-18	GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY	Impstoffe zur transkutanen immunisierung gegen reisediarrhö
KR20030065965A (ko) *	2002-02-02	2003-08-09	주식회사 두산	리소포스파티딜에탄올아민을 유효성분으로 함유하는 피부미백용 조성물
EP1393719A1 (de) *	2002-08-23	2004-03-03	Munich Biotech AG	Camptothecin-Carboxylat Formulierungen
MXPA05000632A (es) *	2002-07-15	2005-03-31	Alcon Inc	Composiciones para implante farmaceuticas, lipofilas, no polimericas para uso intraocular.
US20070184089A1 (en) *	2002-07-15	2007-08-09	Alcon, Inc.	Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
ITMI20021684A1 (it) *	2002-07-29	2004-01-29	Therapicon Srl	Composizione farmaceutica di peptide nasale
US7473432B2 (en)	2002-10-11	2009-01-06	Idea Ag	NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US9498454B2 (en)	2003-02-24	2016-11-22	Pharmaceutical Productions Inc.	Transmucosal drug delivery system
KR20120066688A (ko) *	2003-02-24	2012-06-22	파마슈티칼 프로덕션스, 인크.	경점막 약물 전달 시스템
US10172810B2 (en)	2003-02-24	2019-01-08	Pharmaceutical Productions, Inc.	Transmucosal ketamine delivery composition
US9358296B2 (en)	2003-02-24	2016-06-07	Pharmaceutical Productions Inc.	Transmucosal drug delivery system
US9254294B2 (en)	2003-02-24	2016-02-09	Pharmaceutical Productions Inc.	Transmucosal hormone delivery system
US7812120B2 (en)	2003-03-21	2010-10-12	Par Pharmaceutical, Inc.	Nasal calcitonin formulations containing chlorobutanol
GB0404693D0 (en) *	2004-03-02	2004-04-07	Univ London	Pharmaceutical preparations for the treatment of ocular surface and other disorders
UA89513C2 (uk) *	2004-12-03	2010-02-10	Элан Фарма Интернешнл Лтд.	Стабільна композиція з наночастинок ралоксифену гідрохлориду
EA015102B1 (ru) *	2005-06-03	2011-06-30	Элан Фарма Интернэшнл Лтд.	Препараты наночастиц мезилата иматиниба
AU2008279584A1 (en) *	2007-04-27	2009-01-29	Dow Global Technologies Inc.	Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
EP2268265A2 (de) *	2008-03-21	2011-01-05	Elan Pharma International Limited	Zusammensetzungen zur situsspezifischen abgabe von imatinib und anwendungsverfahren
JP5341532B2 (ja) *	2009-01-19	2013-11-13	第一電子工業株式会社	１対の誤嵌合防止キー及び該キーを用いた電気コネクタ
DE102009008094A1 (de)	2009-02-09	2010-08-19	Barnikol-Keuten, Doris, Dr.	In situ Haft-Gelbildende Zubereitungen, insbesondere zur topischen Anwendung auf befeuchtete Haut/Schleimhaut
CZ308596B6 (cs) *	2017-04-03	2020-12-23	Ústav molekulární genetiky AV ČR, v. v. i.	Deriváty fosfolipidů a jejich použití jako léčiva

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4159988A (en) *	1974-08-06	1979-07-03	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	Synthetic phospholipids, a process for their manufacture and their use
GB2051574B (en) *	1979-05-10	1984-01-18	Kyoto Pharma Ind	Adjuvant for promoting absorption of pharmacologically active substances through the rectum
EP0037943B1 (de) *	1980-03-31	1985-08-14	Teijin Limited	Pharmazeutische Zusammensetzung zur rektalen Verabreichung und daraus hergestellte Zäpfchen
US4619795A (en) *	1984-12-24	1986-10-28	Technicon Instruments Corp.	Method for preparing lipid vesicles
IE59067B1 (en) *	1985-04-02	1993-12-15	Yesair David W	Composition for delivery of orally administered drugs and other substances
US4861580A (en) *	1985-10-15	1989-08-29	The Liposome Company, Inc.	Composition using salt form of organic acid derivative of alpha-tocopheral
US4923854A (en) *	1986-01-22	1990-05-08	The Liposome Company, Inc.	Solubilization of hydrophobic materials using lysophospholipid
NZ222907A (en) *	1986-12-16	1990-08-28	Novo Industri As	Preparation for intranasal administration containing a phospholipid absorption enhancing system
CA1335076C (en) *	1987-04-01	1995-04-04	Hanna R. Kowarski	Pharmaceutical composition and method for intranasal administration
GB8712176D0 (en) *	1987-05-22	1987-06-24	Cosmas Damian Ltd	Drug delivery system

1990
- 1990-02-14 AU AU51736/90A patent/AU639228B2/en not_active Ceased
- 1990-02-14 AT AT90904004T patent/ATE138071T1/de not_active IP Right Cessation
- 1990-02-14 CA CA002045469A patent/CA2045469A1/en not_active Abandoned
- 1990-02-14 EP EP90904004A patent/EP0458894B1/de not_active Expired - Lifetime
- 1990-02-14 JP JP2504047A patent/JPH05500203A/ja active Pending
- 1990-02-14 WO PCT/US1990/000841 patent/WO1990009385A1/en not_active Ceased
- 1990-02-14 DE DE69027022T patent/DE69027022T2/de not_active Expired - Fee Related
- 1990-02-14 KR KR1019910700796A patent/KR0157428B1/ko not_active Expired - Fee Related
- 1990-02-14 ES ES90904004T patent/ES2089011T3/es not_active Expired - Lifetime
- 1990-02-14 DK DK90904004.0T patent/DK0458894T3/da active
1991
- 1991-08-27 US US07/758,276 patent/US5200393A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JPH05500203A (ja)	1993-01-21
EP0458894A1 (de)	1991-12-04
AU639228B2 (en)	1993-07-22
DE69027022T2 (de)	1996-11-28
US5200393A (en)	1993-04-06
AU5173690A (en)	1990-09-05
KR0157428B1 (ko)	1998-11-16
EP0458894B1 (de)	1996-05-15
KR920700679A (ko)	1992-08-10
WO1990009385A1 (en)	1990-08-23
ES2089011T3 (es)	1996-10-01
CA2045469A1 (en)	1990-08-18
DK0458894T3 (da)	1996-10-07
DE69027022D1 (de)	1996-06-20
EP0458894A4 (de)	1991-10-01

Legal Events

Date	Code	Title	Description
1996-12-15	UEP	Publication of translation of european patent specification
2006-11-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69027022D1 (de)	1996-06-20	Lipidhilfstoffe für verabreichung durch die nase und örtliche anwendung
ES2526707T3 (es)	2015-01-14	Purificación y estabilización de péptidos y proteínas en agentes farmacéuticos
US7597901B2 (en)	2009-10-06	System for delivering a composition to the nasal membrane and method of using the same
UA41502C2 (uk)	2001-09-17	Стабілізований фармацевтичний препарат, який містить гормон росту і гістидин, кристали гормону росту, що містять гістидин, та спосіб їх одержання
RU95112536A (ru)	1996-12-20	Способы пульсирующего системного введения активного фрагмента паратиреоидного гормона (ртн) и фармацевтические композиции, содержащие биологически активный n-концевой фрагмент паратиреоидного гормона (ртн)
BR9906920A (pt)	2000-10-10	"tts contendo um antioxidante"
DE69301920T2 (de)	1996-08-08	Arzneimittel zur transmucosalen verabreichung von peptiden
ATE84968T1 (de)	1993-02-15	Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge.
DE69129110D1 (de)	1998-04-23	Pharmazeutische zubereitung enthaltend n-glykofurole und n-äthylenglykole
ES2124260T3 (es)	1999-02-01	Respiracion liquida parcial de fluorocarbonos.
DE69431533D1 (de)	2002-11-14	Dosierungsform zur verabreichung von flüssige arzneimittel formulierung
AR020288A1 (es)	2002-05-02	Emulsion aceite en agua que comprende un agente biologicamente activo micronizado y un sistema emulsionante adecuado.
ES2162927T3 (es)	2002-01-16	Formulacion para la aplicacion por inhalacion.
HUP0204159A2 (hu)	2003-04-28	Prosztaglandin-készítmények és alkalmazásuk erekciós zavarok kezelésére szolgáló gyógyszerek előállítására
DE69531741D1 (de)	2003-10-16	Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
HUP0102337A2 (hu)	2002-03-28	Eljárás gyulladásgátló, különösen fertőtlenítő hatású és/vagy sebgyógyulást elősegítő szerek felső légutakba és/vagy fülbe történő beadására szolgáló készítmények előállítására
MY107088A (en)	1995-09-30	Plaster used as therapeutic system for the administration of active substances to the skin, which exhibits a graduated active substance release,process for the production of the plaster and use thereof
ATE364391T1 (de)	2007-07-15	Arzneiformulierung enthaltend ciclosporin und deren verwendung
EP1684681B1 (de)	2018-10-24	Mischung zur transdermalen abgabe von verbindungen mit niedrigem und hohem molekulargewicht
AU625402B2 (en)	1992-07-09	Transdermal system exhibiting graduated drug release and its use for the local or systemic administration of active substances
BRPI0014878B8 (pt)	2021-05-25	composição farmacêutica contendo ciclosonida para aplicação à mucosa
KR970032872A (ko)	1997-07-22	아세틸살리실산을 함유하는 피부 손상 처치용 약물
RU94010496A (ru)	1997-05-10	Ноотропное средство и лекарственный состав ноотропного средства
DE59914183D1 (de)	2007-03-22	Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
JP2012193159A (ja)	2012-10-11	鼻用スプレー